Founded in 2020 and dedicated to the development, production and sales of high-end drugs, Arthur Pharma Group is committed to becoming the first domestic drugmaker to file the FDA application for continuous manufacturing.
Arthur Pharma Group (Chinese: 亚瑟医药) recently announced that it has closed a Series A funding round worth over tens of millions of USD. The investment is led by Addor Capital, with participation from Zhejiang Changxing Financial Holding Group, Jiaxing Tech City Fund, Hangzhou Ruiying Assets, Huzhou Xincheng, and other venture funds.
The proceeds will be utilized to build up the injection production line as well as the pipelines centered on the upstream and downstream value chain of high-end formulations, which will be compliant with the GMP standards of the US, EU, and China. Meanwhile, Arthur Pharma will be committed to filing the first FDA application for continuous manufacturing in China.
To date, Arthur Pharma has established two R&D centers covering 2,000 square meters and four API production lines. According to its official website, with two R&D centers located in Princeton, the US and Jiaxing, China, the company has the capacity to develop tablets, capsules, injections, semi-solid and other dosage forms. Through CMO cooperation, the company has several manufacturing facilities in North America and Asia.
The founder and CEO of the company, Dr. Liu Hongbin, held senior management positions in world-leading companies such as McKinsey, Novartis and Pfizer, and has rich international experience in the field of high-end formulation research and production.
According to lead investor Dr. Meng Xiaoying from Addor Capital, Arthur Pharma is experienced in the upstream and downstream pipelines of the high-end pharmaceutical products.
Meng added that its innovative understanding of the manufacturing process stands out as well. These core strengths align perfectly with Addor Capital’s investment logic of in-depth layout within the pharmaceutical industry chain, she explained.
Liu, the founder, said that the company would further optimize the R&D pipeline layout through series A financing and complete the construction of an injection production line compliant with FDA standards.
Arthur Pharma would also continue the global layout of continuous manufacturing.
